Retroclavicular Approach to Infraclavicular Block

Bupivacaine Clinical Trial

Official title: Minimum Effective Volume of Bupivacaine 0.5% for Ultrasound-guided Retroclavicular Approach to Infraclavicular Brachial Plexus Block

Status Completed

Clinical Trial Summary

In this study, the primary objective was to estimate the minimum effective volume of bupivacaine 0.5% resulting in successful block in 50% of patients (MEV50) for ultrasound-guided retroclavicular approach to infraclavicular brachial plexus block.

Clinical Trial Description

Two rules were used to stop the study. First stopping rule was a fixed-sample-size. The investigators used an up-and-down method to estimate the threshold for an all-or-none response for present study design. Therefore, for sample size calculation, the investigators applied the formula by Dixon and Massey, n=2(SD/SEM)2 (SD: standard deviation and SEM: standard error of mean). Second stopping rule included demonstration of minimum of five consecutive up-and-down sequences. On the basis of previous studies with similar binary outcomes, the investigators estimated that a priori a minimum of five negative-positive up-and down deflections was required to calculate MEV50. ;

Related Conditions & MeSH terms

• Bupivacaine

• NCT number: NCT03472911
• Study type: Observational
• Source: Antalya Training and Research Hospital
• Status: Completed
• Start date: January 8, 2018
• Completion date: March 15, 2018